CN116173077A - 动物双歧杆菌的应用 - Google Patents
动物双歧杆菌的应用 Download PDFInfo
- Publication number
- CN116173077A CN116173077A CN202310277265.5A CN202310277265A CN116173077A CN 116173077 A CN116173077 A CN 116173077A CN 202310277265 A CN202310277265 A CN 202310277265A CN 116173077 A CN116173077 A CN 116173077A
- Authority
- CN
- China
- Prior art keywords
- rats
- offspring
- atrial
- bifidobacterium animalis
- cold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001134770 Bifidobacterium animalis Species 0.000 title claims abstract description 34
- 229940118852 bifidobacterium animalis Drugs 0.000 title claims abstract description 34
- 206010003658 Atrial Fibrillation Diseases 0.000 claims abstract description 54
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000035935 pregnancy Effects 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 235000013406 prebiotics Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 235000015203 fruit juice Nutrition 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 240000002900 Arthrospira platensis Species 0.000 claims description 3
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 3
- 235000015140 cultured milk Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- 235000021105 fermented cheese Nutrition 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229940082787 spirulina Drugs 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims 1
- 241000186000 Bifidobacterium Species 0.000 abstract description 49
- 241000700159 Rattus Species 0.000 description 98
- 230000001746 atrial effect Effects 0.000 description 53
- 241001465754 Metazoa Species 0.000 description 39
- 239000002904 solvent Substances 0.000 description 18
- 206010016654 Fibrosis Diseases 0.000 description 15
- 230000004761 fibrosis Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 11
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 10
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 10
- 238000010186 staining Methods 0.000 description 9
- 230000009469 supplementation Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- 238000013042 tunel staining Methods 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 241000186012 Bifidobacterium breve Species 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 3
- 101150017888 Bcl2 gene Proteins 0.000 description 3
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 3
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 3
- 108700000707 bcl-2-Associated X Proteins 0.000 description 3
- 102000055102 bcl-2-Associated X Human genes 0.000 description 3
- 229940009291 bifidobacterium longum Drugs 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 101710170789 Protein bax Proteins 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 208000008434 Severe Acute Malnutrition Diseases 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000169 anti-osteoclastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000037024 effective refractory period Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000004207 intestinal integrity Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 210000002707 regulatory b cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及双歧杆菌领域，公开了动物双歧杆菌或包含动物双歧杆菌的食品、药物用于预防和/或治疗房颤的应用。本发明填补了现有技术防治妊娠期寒冷暴露所致子代房颤的空白，创新性的提出动物双歧杆菌用于防治妊娠期寒冷暴露所致的子代房颤的具体应用。
Description
技术领域
本发明涉及双歧杆菌领域，更具体地涉及动物双歧杆菌的应用。
背景技术
大量研究证实，双歧杆菌在帕金森病、结肠炎、糖尿病和肿瘤等多种疾病中具有潜在的作用。双歧杆菌通过改善肠道完整性、降低内毒素和三甲胺水平，恢复结肠淋巴结和主动脉中Th17和Treg细胞含量，显著降低盐敏感性高血压大鼠的血压水平。短双歧杆菌可通过调节阿尔茨海默病小鼠肠道菌群和微生物代谢物来缓解认知障碍。长双歧杆菌还通过增强调节B细胞的抗破骨细胞和免疫调节潜力来改善卵巢切除术诱导的骨质流失。新近研究显示，短双歧杆菌M-16V(B.breve M-16V)显著抑制纳米聚苯乙烯暴露小鼠体内Th2和Th17淋巴细胞亚群。同时，短双歧杆菌M-16V可激活MyD88表达并促进Th1相关细胞因子IL-12的产生。动物双歧杆菌MSMC83改善D-半乳糖诱导大鼠的氧化应激和肠道菌群。
双歧杆菌在多种疾病中得到越来越广泛的应用。研究显示，与同龄健康婴儿相比，患有严重急性营养不良的婴儿肠道双歧杆菌丰度显著降低。安慰剂随机对照试验结果显示，给予商业化婴儿双歧杆菌菌株(EVC001)和母乳寡聚糖，可明显增加婴儿肠道中双歧杆菌丰度，减少肠道炎症标志物，促进婴儿体重增加，改善婴儿营养不良状态。Meta分析显示，双歧杆菌四联活菌联合美沙拉胺在中国治疗溃疡性结肠炎具有令人满意的效果，且安全性较高。一项随机双盲实验对慢性便秘的老年人进行研究发现，长双歧杆菌BB536明显改善老年人便秘症状，提示长双歧杆菌是便秘的潜在治疗菌株。双歧杆菌在肿瘤治疗领域也具有重要作用。最新研究报道，以双歧杆菌为载体开发一种新的药物递送系统，可实现抗肿瘤药物的靶向递送，有效抑制肿瘤生长。补充动物双歧杆菌可通过调控肠道菌群和炎症反应，增强伊立替康的抗肿瘤作用，提示动物双歧杆菌可作为一种营养补充剂在抗肿瘤治疗中发挥重要作用。此外，单中心随机双盲试验证明，动物双歧杆菌乳酸亚种MH-02干预明显缓解接受结肠息肉内径切除术的患者排便困难症状，缩短肠道功能恢复时间。动物双歧杆菌已经被批准作为医用益生菌，具有多种作用，包括促进婴幼儿肠道菌群平衡、提高抵抗力、预防婴幼儿湿疹等过敏性疾病、降低呼吸道疾病感染率、促进婴儿免疫系统成熟、促进生长发育、预防腹泻、防止轮状病毒感染、降低便秘和坏死性小肠结肠炎发生等。
近年来，人们更加关注妊娠期生活暴露对子代健康的影响。大量研究证明，妊娠期生活暴露可改变子代肠道菌群组成和结构，从而增加子代多种疾病发生风险。本发明创造性的发现妊娠期寒冷暴露对子代肠道菌群有着显著的影响，且增加子代房颤易感性。
发明内容
为解决现有技术中的上述技术问题，本发明提供动物双歧杆菌的应用。
本发明采用的具体方案为：动物双歧杆菌或包含动物双歧杆菌的食品、药物用于预防和/或治疗房颤的应用。
所述预防和/或治疗子代房颤为妊娠期寒冷暴露所致的子代房颤。
所述食品为膳食补充剂、益生元、固体饮料、乳制品中的任意一种。
所述益生元为低聚果糖或低聚木糖或螺旋藻。
所述固体饮料为果汁。
所述乳制品为酸奶,风味发酵乳或奶酪中的任意一种或几种。
所述食品为丸剂、胶囊剂、片剂、粉剂、或液体剂。
所述药物中含有动物双歧杆菌的剂量为活菌数≥40亿/袋。
本发明相对于现有技术具有如下有益效果：
本发明公开了动物双歧杆菌可通过调控免疫稳态，降低循环和心房炎症反应，防止妊娠期寒冷暴露所致子代房颤发生，动物双歧杆菌可作为房颤的防治靶点。动物双歧杆菌适用于妊娠期寒冷暴露所致子代房颤发生，调控机体免疫稳态，降低机体炎症水平，本发明填补了现有技术防治妊娠期寒冷暴露所致子代房颤的空白，创新性的提出动物双歧杆菌用于防治妊娠期寒冷暴露所致的子代房颤的具体应用。
附图说明
图1为室温子代和寒冷子代组大鼠心房电生理检测结果-大鼠心房起搏代表心电图；
图2为室温子代和寒冷子代组大鼠心房电生理检测结果-房颤诱发率；
图3为室温子代和寒冷子代组大鼠心房电生理检测结果-房颤持续时间；
图4为室温子代和寒冷子代组大鼠心房电生理检测结果-心房有效不应期(n＝10)；
图5为室温子代和寒冷子代组大鼠心房纤维化和凋亡-Masson染色观察室温子代组和寒冷子代组大鼠心房组织胶原沉积代表图，放大倍数为200倍，比例尺＝50μm；
图6为室温子代和寒冷子代组大鼠心房纤维化和凋亡-胶原蛋白沉积统计图；
图7为室温子代和寒冷子代组大鼠心房纤维化和凋亡-Tunel染色显示室温子代组和寒冷子代组大鼠心房凋亡细胞代表图；
图8为室温子代和寒冷子代组大鼠心房纤维化和凋亡-凋亡细胞百分比图(n＝4)；
图9为室温子代和寒冷子代组大鼠心房纤维化和凋亡相关蛋白表达-大鼠心房组织TGF-β1和α-SMA蛋白表达的代表性条带；
图10为室温子代和寒冷子代组大鼠心房纤维化和凋亡相关蛋白表达-TGF-β1和α-SMA蛋白表达定量统计图；
图11为室温子代和寒冷子代组大鼠心房纤维化和凋亡相关蛋白表达-大鼠心房Bcl2和BAX蛋白表达的代表性条带；
图12为室温子代和寒冷子代组大鼠心房纤维化和凋亡相关蛋白表达-Bcl2和BAX蛋白表达定量统计图(n＝6)；
图13为补充动物双歧杆菌降低寒冷子代大鼠房颤易感性-大鼠心房起搏代表心电图；
图14为补充动物双歧杆菌降低寒冷子代大鼠房颤易感性-大鼠房颤诱发率图；
图15为补充动物双歧杆菌降低寒冷子代大鼠房颤易感性-大鼠房颤持续时间；
图16为溶剂对照组和补充动物双歧杆菌组大鼠心房纤维化和凋亡-大鼠心房组织Masson染色代表图
图17为溶剂对照组和补充动物双歧杆菌组大鼠心房纤维化和凋亡-胶原蛋白沉积统计图
图18为溶剂对照组和补充动物双歧杆菌组大鼠心房纤维化和凋亡-大鼠心房组织Tunel染色代表图
图19为溶剂对照组和补充动物双歧杆菌组大鼠心房纤维化和凋亡-凋亡细胞百分比(n＝4)；
图20为溶剂对照组和补充动物双歧杆菌组寒冷子代大鼠心房纤维化和凋亡相关蛋白表达-大鼠心房TGF-β1和α-SMA的蛋白代表条带；
图21为溶剂对照组和补充动物双歧杆菌组寒冷子代大鼠心房纤维化和凋亡相关蛋白表达-TGF-β1和α-SMA蛋白表达定量统计图；
图22为溶剂对照组和补充动物双歧杆菌组寒冷子代大鼠心房纤维化和凋亡相关蛋白表达-大鼠心房Bcl2和BAX的蛋白代表条带；
图23为溶剂对照组和补充动物双歧杆菌组寒冷子代大鼠心房纤维化和凋亡相关蛋白表达-Bcl2和BAX蛋白表达定量统计图(n＝6)；
图24为溶剂对照组和补充动物双歧杆菌组大鼠免疫T细胞亚群百分比-大鼠脾脏CD4T细胞和CD8 T细胞百分比；
图25为溶剂对照组和补充动物双歧杆菌组大鼠免疫T细胞亚群百分比-大鼠脾脏CD4/CD8 T细胞比率统计图；
图26为溶剂对照组和补充动物双歧杆菌组大鼠免疫T细胞亚群百分比-大鼠血液中CD4 T细胞和CD8 T细胞百分比；
图27为溶剂对照组和补充动物双歧杆菌组大鼠免疫T细胞亚群百分比-大鼠血液CD4/CD8 T细胞比率统计图(n＝4)；
图28为大鼠血浆和心房炎症因子水平-大鼠血浆IFN-γ、TNF-α、IL-5和IL-6水平(n＝8)
图29为大鼠血浆和心房炎症因子水平-大鼠心房IFN-γ、TNF-α、IL-5和IL-6水平(n＝8)。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明了，下面通过附图中示出的具体实施例来描述本发明。但是应该理解，这些描述只是示例性的，而并非要限制本发明的范围。此外，在以下说明中，省略了对公知结构和技术的描述，以避免不必要地混淆本发明的概念。
结合附图1-29，本发明公开了动物双歧杆菌(儿童益生菌粉，属于固体饮料)或包含动物双歧杆菌的食品、药物用于预防和/或治疗子代房颤的应用。所述预防和/或治疗子代房颤为妊娠期寒冷暴露所致的子代房颤。所述食品为膳食补充剂、益生元、固体饮料、乳制品中的任意一种。所述益生元为低聚果糖或低聚木糖或螺旋藻。所述固体饮料为果汁。所述乳制品为酸奶,风味发酵乳或奶酪中的任意一种或几种。所述食品为丸剂、胶囊剂、片剂、粉剂、或液体剂。所述药物中含有动物双歧杆菌的剂量为活菌数≥40亿/袋(科汉森Bb-12)。
实施例1
动物双歧杆菌(Chr.Hansen BB-12儿童益生菌粉，科汉森Bb-12)用于防治妊娠期寒冷暴露所致的子代房颤的应用。
实施例2
动物双歧杆菌添加至酸奶中用于防治妊娠期寒冷暴露所致的子代房颤的应用。
实施例3
动物双歧杆菌添加至果汁中用于防治子代房颤的应用。
实施例4
双歧杆菌与解痉剂联合使用可治疗成人炎症性肠病(活菌数≥1.0*107CFU/粒胶囊，一日两次，每次2-4粒)。
结合实施例1-3，,探究妊娠期寒冷暴露对子代大鼠房颤易感性的影响，本发明构建妊娠期寒冷暴露大鼠模型，大鼠受孕后置于4±1℃的恒温饲养箱中进行寒冷暴露18天，然后置于室温条件下分娩和喂养子代，妊娠期寒冷暴露孕鼠所生的子代为寒冷子代大鼠。子代大鼠成年后，对室温子代和寒冷子代大鼠进行心房电生理检测观察房颤易感性，进行心房病理染色和Western blot观察心房结构重构相关指标。
为探究双歧杆菌对寒冷子代大鼠房颤的影响，本发明随机将寒冷子代大鼠分为两组，一组给予对照溶剂，一组给予动物双歧杆菌灌胃(2×109CFU/mL),大鼠在1～3周龄时给予100μl动物双歧杆菌溶液灌胃，在3～8周龄时给予500μl动物双歧杆菌溶液灌胃，一周一次。子代大鼠成年后进行心房电生理检测，观察房颤诱发率和持续时间变化；心房病理染色观察心房纤维化和凋亡水平；Western blot检测心房纤维化相关蛋白TGF-β1和α-SMA及凋亡相关指标BAX和Bcl2表达水平；流式细胞术检测脾脏和循环CD4+、CD8+和Treg细胞水平；ELISA检测心脏和循环炎症因子IL5、IL-6、TNF-α和IFN-γ水平。
试验结果如下：妊娠期寒冷暴露导致子代大鼠房颤易感性增加。
结合附图1-4，本发明中对成年室温子代和寒冷子代大鼠进行心房电生理检测。结果显示，与室温子代大鼠相比，寒冷子代大鼠房颤诱发率和持续时间显著增加(P＝0.0198)，持续时间明显延长(P＝0.0399)，心房有效不应期无明显改变。
妊娠期寒冷暴露对子代大鼠心房肌纤维化和细胞凋亡的影响
心房肌纤维化和细胞凋亡是心房结构重构的重要标志。本发明对寒冷子代大鼠和室温子代大鼠心房组织进行Masson染色和Tunel染色。Masson染色结果显示，与室温子代大鼠相比，寒冷子代大鼠心房组织胶原沉积增加(P＝0.0011)。Tunel染色显示，与室温子代大鼠相比，寒冷子代大鼠心房凋亡细胞百分数显著增加(P＝0.0072)。结合附图5-8，结果提示，妊娠期寒冷暴露增加子代大鼠心房肌纤维化和细胞凋亡水平。
妊娠期寒冷暴露对子代大鼠心房纤维化和凋亡相关蛋白的影响
结合附图9-12，本发明进一步对室温子代和寒冷子代大鼠心房纤维化和凋亡相关蛋白进行检测。与室温子代大鼠相比，寒冷子代大鼠心房纤维化相关蛋白TGF-β1(P＝0.0053)和α-SMA(P＝0.0094)，以及促凋亡相关蛋白BAX(P＝0.0012)表达显著上调，抗凋亡蛋白Bcl2表达显著下调(P＝0.0146)。
补充动物双歧杆菌明显降低寒冷子代大鼠房颤易感性。
结合附图13-15，本发明将成年对照组大鼠和动物双歧杆菌组大鼠进行心房电生理检测，结果显示，与对照组大鼠相比，动物双歧杆菌组大鼠房颤诱发明显降低(P＝0.0406)，房颤持续时间显著缩短(P＝0.0368)，提示动物双歧杆菌可降低寒冷子代大鼠房颤易感性。图15中Vehicle代表给予溶剂的对照组寒冷子代大鼠，B.animals代表给予双歧杆菌的寒冷子代大鼠；n＝8。
补充动物双歧杆菌改善寒冷子代心房纤维化和凋亡水平
结合附图16-19，成年对照组和动物双歧杆菌大鼠进行电生理检测后，取心房组织进行病理染色。Masson染色结果显示，与对照组大鼠相比，动物双歧杆菌组大鼠心房胶原沉积明显减少，纤维化程度减轻(P＝0.0012)；心房Tunel染色结果显示，与对照组大鼠相比，动物双歧杆菌组大鼠心房凋亡细胞百分比明显降低(P＝0.0005)。这些结果表明，补充动物双歧杆菌可明显改善寒冷子代大鼠心房纤维化和凋亡水平。
补充动物双歧杆菌降低寒冷子代大鼠心房纤维化和凋亡相关蛋白表达
结合附图20-23，本发明对两组大鼠心房组织进行Western blot检测，结果显示，与溶剂对照组相比，补充动物双歧杆菌组寒冷子代大鼠心房TGF-β1(P＜0.0001)和α-SMA(P＝0.0002)表达显著下调，BAX(P＝0.0002)表达减少，Bcl2(P＝0.0356)表达显著增加。这些结果提示，补充动物双歧杆菌可降低寒冷子代大鼠心房纤维化和凋亡水平。
补充动物双歧杆菌增加寒冷子代大鼠CD4/CD8 T细胞比率
结合附图24-27，双歧杆菌具有免疫调节作用，免疫-炎症紊乱是心房结构重构的重要机制之一。为了探究双歧杆菌对寒冷子代大鼠免疫T细胞的影响，本发明使用流式细胞术对溶剂对照组和补充动物双歧杆菌组寒冷子代大鼠脾脏和血液进行检测。结果显示，与溶剂对照组相比，补充动物双歧杆菌组寒冷子代大鼠脾脏(P＝0.0116)和血液(P＝0.0202)中CD4/CD8 T细胞比例显著增加，提示补充动物双歧杆菌逆转妊娠期寒冷暴露导致的子代大鼠免疫失衡。
补充动物双歧杆菌降低寒冷子代大鼠血浆和心房炎症因子水平
结合附图28-29，为进一步验证补充动物双歧杆菌是否可改善大鼠体内炎症水平，本发明使用ELISA试剂盒对大鼠血浆和心房组织进行炎症因子检测。结果显示，与溶剂对照组相比，补充双歧杆菌组寒冷子代大鼠血浆IFN-γ(P＝0.0004)、TNF-α(P＝0.0015)和IL-6(P＜0.0001)水平显著降低，且心房组织中IFN-γ(P＝0.0061)、IL-5(P＝0.001)和IL-6(P＝0.0002)水平也明显降低。这提示补充动物双歧杆菌可降低寒冷子代大鼠系统性和心房局部炎症因子水平，改善妊娠期寒冷暴露所致的子代大鼠机体高炎症状态。
本发明证明动物双歧杆菌可通过调控免疫稳态，降低循环和心房炎症反应，防止妊娠期寒冷暴露所致子代房颤发生，提示可作为房颤的防治靶点。既往研究证明双歧杆菌可调控新生儿免疫系统发育，可降低免疫相关疾病发生风险。动物双歧杆菌适用于妊娠期寒冷暴露所致子代房颤发生，调控机体免疫稳态，降低机体炎症水平。
以上附图及解释说明仅为本发明的一种具体实施方式，但本发明的具体保护范围不仅限以上解释说明，任何在本发明揭露的技术思路范围内，及根据本发明的技术方案加以简单地替换或改变，都应在本发明的保护范围之内。
Claims (8)
1.动物双歧杆菌或包含动物双歧杆菌的食品、药物用于预防和/或治疗房颤的应用。
2.根据权利要求1所述的动物双歧杆菌的应用，其特征在于，所述预防和/或治疗房颤为妊娠期寒冷暴露所致的子代房颤。
3.根据权利要求1所述的动物双歧杆菌的应用，其特征在于，所述食品为膳食补充剂、益生元、固体饮料、乳制品中的任意一种。
4.根据权利要求3所述的动物双歧杆菌的应用，其特征在于，所述益生元为低聚果糖或低聚木糖或螺旋藻。
5.根据权利要求3所述的动物双歧杆菌的应用，其特征在于，所述固体饮料为果汁。
6.根据权利要求3所述的动物双歧杆菌的应用，其特征在于，所述乳制品为酸奶,风味发酵乳或奶酪中的任意一种或几种。
7.根据权利要求4-6任一项所述的动物双歧杆菌的应用，其特征在于，所述食品为丸剂、胶囊剂、片剂、粉剂、液体剂。
8.根据权利要求1所述的动物双歧杆菌的应用，其特征在于，所述药物中含有动物双歧杆菌的剂量为活菌数≥40亿/袋。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310277265.5A CN116173077A (zh) | 2023-03-21 | 2023-03-21 | 动物双歧杆菌的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310277265.5A CN116173077A (zh) | 2023-03-21 | 2023-03-21 | 动物双歧杆菌的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116173077A true CN116173077A (zh) | 2023-05-30 |
Family
ID=86434621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310277265.5A Pending CN116173077A (zh) | 2023-03-21 | 2023-03-21 | 动物双歧杆菌的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116173077A (zh) |
-
2023
- 2023-03-21 CN CN202310277265.5A patent/CN116173077A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abbasi et al. | The biological activities of postbiotics in gastrointestinal disorders | |
| US10016468B2 (en) | Method and compositions for treating cancer using probiotics | |
| EP3349763B1 (en) | Composition for use in microbiota modulation | |
| TWI463986B (zh) | 胚芽乳酸桿菌ｃｍｕ９９５菌株之新用途 | |
| US20100166721A1 (en) | Probotic compositions and uses thereof | |
| US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| EP2546330B1 (en) | Lactic acid bacterium-containing preparation | |
| Cabana et al. | Probiotics in primary care pediatrics | |
| Kumari et al. | Probiotics, prebiotics, and synbiotics: Current status and future uses for human health | |
| CN106036911A (zh) | 一种调节血糖水平的益生菌膳食组合物及功能食品 | |
| JP7434375B2 (ja) | 腸管免疫調節のための新規なプロバイオティック組成物 | |
| CN106994134B (zh) | 肠道益生菌在预防和/或治疗糖尿病及其相关疾病中的应用 | |
| WO2015093937A1 (en) | Lactobacillus salivarius for the treatment of mastitis | |
| CN111528479A (zh) | 一种缓解特应性皮炎功能的益生菌和益生元组合物及应用 | |
| Yamashiro et al. | Beneficial microbes for premature infants, and children with malignancy undergoing chemotherapy | |
| CN112273657A (zh) | 用于预防或改善过敏性疾病的益生菌组合物、制法和应用 | |
| EP2575834B1 (en) | Probiotic strains for use in improving transepithelial resistance | |
| Lima et al. | Effect of probiotics on the maintenance of intestinal homeostasis after chemotherapy: systematic review and meta-analysis of pre-clinical studies | |
| WO2008002484A2 (en) | Novel lactobacillus bulgaricus strain and compositions | |
| Surolia et al. | Synbiotics: a promising approach for improving human health | |
| Arora et al. | Therapeutic potential of probiotics: A ray of hope or nightmare? | |
| CN116173077A (zh) | 动物双歧杆菌的应用 | |
| CN110448569B (zh) | 一种具有止泻功效的组合物及其制备方法和其应用 | |
| Sako et al. | The world’s oldest probiotic: perspectives for health claims | |
| Murphy et al. | Probiotics as curators of a healthy gut microbiota: Delivering the solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |